- Home
- ADIL vs BDRX Comparison
ADIL vs BDRX Comparison
Compare ADIL & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- BDRX
- Stock Information
- Founded
- ADIL 2010
- BDRX 2000
- Country
- ADIL United States
- BDRX United Kingdom
- Employees
- ADIL N/A
- BDRX N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- BDRX Health Care
- Exchange
- ADIL Nasdaq
- BDRX Nasdaq
- Market Cap
- ADIL 4.3M
- BDRX 3.5M
- IPO Year
- ADIL 2018
- BDRX N/A
- Fundamental
- Price
- ADIL $0.69
- BDRX $1.55
- Analyst Decision
- ADIL Strong Buy
- BDRX
- Analyst Count
- ADIL 1
- BDRX 0
- Target Price
- ADIL $8.00
- BDRX N/A
- AVG Volume (30 Days)
- ADIL 47.3K
- BDRX 1.2M
- Earning Date
- ADIL 05-13-2025
- BDRX 05-09-2025
- Dividend Yield
- ADIL N/A
- BDRX N/A
- EPS Growth
- ADIL N/A
- BDRX N/A
- EPS
- ADIL N/A
- BDRX N/A
- Revenue
- ADIL N/A
- BDRX N/A
- Revenue This Year
- ADIL N/A
- BDRX N/A
- Revenue Next Year
- ADIL N/A
- BDRX N/A
- P/E Ratio
- ADIL N/A
- BDRX N/A
- Revenue Growth
- ADIL N/A
- BDRX N/A
- 52 Week Low
- ADIL $0.58
- BDRX $1.14
- 52 Week High
- ADIL $3.00
- BDRX $74.00
- Technical
- Relative Strength Index (RSI)
- ADIL 46.74
- BDRX 43.94
- Support Level
- ADIL $0.65
- BDRX $1.24
- Resistance Level
- ADIL $0.74
- BDRX $1.52
- Average True Range (ATR)
- ADIL 0.07
- BDRX 0.20
- MACD
- ADIL 0.00
- BDRX 0.07
- Stochastic Oscillator
- ADIL 47.73
- BDRX 49.21
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.